First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306
Version 2 2025-03-13, 16:00
Version 1 2025-01-16, 16:55
media
posted on 2025-03-13, 16:00 authored by AdisRapid Journals on behalf of:, Jianming Xu, Ken Kato, Richard Hubner, Sook Ryun Park, Takashi Kojima, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Hongqian Wu, Lei Wang, Sebastian Yan, Jingwen Shi, Alysha Kadva, Harry H. Yoon
This article is now published.
There are currently no digital features for this article. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
